Ingevity Corporation · NYSE:NGVT

Ingevity — Q1 2023 Earnings Presentation

22 slides from Ingevity's earnings presentation, May 4, 2023

  1. Slide 1: First Quarter 2023 Earnings Presentation

    FIRST QUARTER 2023 EARNINGS PRESENTATION May 4, 2023

  2. Slide 2: Use of non-GAAP financial measures and forward-looking statements

    Use of non-GAAP financial measures: This presentation includes certain non‐GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. Reconciliations of non‐GAAP financial measures to GAAP financial measures are provided within the Appendix to this presentation. In

  3. Slide 3: Agenda

    AGENDA 1 Quarter highlights and updates 2 Consolidated financial results 3 Segment performance 4 Guidance 5 Q&A 3

  4. Slide 4: Quarter Highlights and Updates

    QUARTER HIGHLIGHTS AND UPDATES Price increases offset volume weakness due to slower than expected recovery in China and continued customer destocking Advanced Polymer Technologies formerly Engineered Polymers, is now a reportable segment separate from Performance Chemicals Beginning in April, crude

  5. Slide 5: First Quarter (Q1) Consolidated Financial Performance

    FIRST QUARTER (Q1) CONSOLIDATED FINANCIAL PERFORMANCE Q1 financials (1) Performance highlights $ in millions except percentage and EPS Q1 Q1 vs PY Sales up ~3% reflecting increased pricing across all segments and the 2023 2022 ∆% inclusion of Ozark, partially offset by weaker volumes $392.6 $382.8 2

  6. Slide 6: Q1 2023 Financial Metrics and Highlights

    Q1 2023 FINANCIAL METRICS AND HIGHLIGHTS Net Sales Free cash flow (1) $ in millions $ in millions Q4  Sales for Q1 2023 set a new  FCF of negative Q4 $20.2 million Q1 record for the company Q3 Q3 383 with higher prices offsetting 122 reflects lower Q2 lower volumes Q2 earnings and 51 39 Q1 49 Q1 s

  7. Slide 7: Performance Chemicals

    PERFORMANCE CHEMICALS Q1 Q1 $ % $ IN MILLIONS VS. PRIOR VS. PRIOR 2023 2022 YEAR YEAR Performance highlights Net Sales 185.6 172.6 13.0 7.5% Industrial Specialties 139.8 144.7 (4.9) (3.4)% Sales of $185.6 million up 8% due to higher pricing across the segment and the addition of Ozark, partially off

  8. Slide 8: Advanced Polymer Technologies

    ADVANCED POLYMER TECHNOLOGIES Q1 Q1 $ % $ IN MILLIONS VS. PRIOR VS. PRIOR 2023 2022 YEAR YEAR Performance highlights Net Sales 65.6 61.8 3.8 6.1% Sales of $65.6 million up 6% as higher prices more than offset volume Segment EBITDA 13.8 10.3 3.5 34.0% declines Segment EBITDA Margin 21.0% 16.7% 430 bp

  9. Slide 9: Performance Materials

    PERFORMANCE MATERIALS Q1 Q1 $ % $ IN MILLIONS VS. PRIOR VS. PRIOR 2023 2022 YEAR YEAR Performance highlights Net Sales 141.4 148.4 (7.0) (4.7)% Sales of $141.4 million down 5% due to lower volumes attributed Segment EBITDA 69.8 77.9 (8.1) (10.4)% primarily to the slower China recovery, partially off

  10. Slide 10: 2023 Guidance and Outlook

    2023 GUIDANCE AND OUTLOOK Opportunities: FY Guidance Financial  Accelerate AFA production and new market FY Guidance metric development Revenue $1.75 - $1.95 billion  Pace of automotive production picks up  China market has strong recovery Adj. EBITDA (1) $450 - $480 million  Infrastructure fund

  11. Slide 11: Investor Day May 22, 2023

    INVESTOR DAY May 22, 2023 11

  12. Slide 12: Thank you for your interest in Ingevity

    FOR MORE INFORMATION Investors John E. Nypaver, Jr. (843) 740 - 2002 Media Caroline Monahan (843) 740 - 2068 Thank you for your interest in Ingevity. 12

  13. Slide 13: Appendix

    APPENDIX 13

  14. Slide 14: Definitions of non-GAAP financial measures

    Ingevity has presented certain financial measures, defined below, which have not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and has provided a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP. These finan

  15. Slide 15: Reconciliation of Net Income and Diluted EPS to Adjusted Earnings

    Reconciliation of Net Income (Loss) (GAAP) and Diluted Earnings (Loss) Per Share (GAAP) to Adjusted Earnings (Loss) (Non-GAAP) and Diluted Adjusted Earnings (Loss) Per Share (Non-GAAP) Three Months Ended March 31, In millions, except per data (unaudited) 2023 2022 Net income (loss) (GAAP) $ 50.7 $ 6

  16. Slide 16: Reconciliation of Net Income to Adjusted EBITDA

    Reconciliation of Net Income (GAAP) to Adjusted EBITDA (Non-GAAP) Three Months Ended March 31, In millions, except percentages (unaudited) 2023 2022 Net income (loss) (GAAP) $ 50.7 $ 60.8 Provision (benefit) for income taxes 13.4 16.8 Interest expense, net 19.6 10.7 Depreciation and amortization 31.

  17. Slide 17: Reconciliation of Gross Profit to Adjusted Gross Profit

    Reconciliation of Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) Three Months Ended March 31, In millions, except percentages (unaudited) 2023 2022 Gross Profit (GAAP) $ 130.4 $ 137.8 Plus: Depreciation and amortization 17.3 16.6 Inventory fair value step-up amortization 0.8 — Adjusted gros

  18. Slide 18: Reconciliations of SG&A to Adjusted SG&A

    Reconciliations of SG&A (GAAP) to Adjusted SG&A (Non-GAAP) Three Months Ended March 31, In millions, except percentages (unaudited) 2023 2022 SG&A (GAAP) $ 48.6 $ 40.0 Research and technical expenses (GAAP) 8.8 7.3 Total SG&A (GAAP) 57.4 47.3 Less: Depreciation and amortization 12.7 10.4 Adjusted SG

  19. Slide 19: Reconciliations of Other (income) expense, net to Adjusted

    Reconciliations of Other (income) expense, net (GAAP) to Adjusted Other (income) expense, net (Non-GAAP) Three Months Ended March 31, In millions, except percentages (unaudited) 2023 2022 Other (income) expense, net (GAAP) $ (18.2) $ (1.4) Less: Gain on strategic investment (19.2) — Depreciation and

  20. Slide 20: Reconciliation of Cash Flow from Operations to Free Cash Flow

    Reconciliation of Cash Flow from Operations (GAAP) to Free Cash Flow (Non-GAAP) Three Months Ended March 31, In millions (unaudited) 2023 2022 Cash Flow from Operations $ 5.2 $ 24.3 Less: Capital Expenditures 25.4 27.6 Free Cash Flow $ (20.2) $ (3.3) 2018 2019 In millions (unaudited) Q1 Q2 Q3 Q4 Q1

  21. Slide 21: Calculation of Net Debt to Adjusted EBITDA Ratio

    Calculation of Net Debt to Adjusted EBITDA Ratio (Non-GAAP) In millions, except ratios (unaudited) March 31, 2023 Notes payable and current maturities of long-term debt $ 0.9 Long-term debt including finance lease obligations 1,502.5 Debt issuance costs 6.2 Total Debt $ 1,509.6 Less: Cash and cash e

  22. Slide 22: Calculation of Historical Net Debt Ratio

    Calculation of Historical Net Debt Ratio (Non-GAAP) December 31, 2022 In millions, except ratios (unaudited) 2019 2020 2021 Q1 Q2 Q3 Q4 Net Debt (1) $ 1,121.0 $ 982.7 $ 928.7 $ 976.7 $ 975.9 $ 1,011.3 $ 1,324.3 Adjusted EBITDA(2) 396.9 397.9 422.2 435.8 439.2 457.9 452.6 Caprolactone Pro Forma (3) 5

Ingevity — Q1 2023 Earnings Presentation on 6ix